首頁 > 市場調查報告書 > 醫療設備

導管心血管設備

市場調查報告書

商品編碼

1425071

經導管心臟瓣膜置換市場 - 2024 年至 2029 年預測

Transcatheter Heart Valve Replacement Market - Forecasts from 2024 to 2029

出版日期: 2024年01月19日 | 出版商:

Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2022年經導管心臟瓣膜置換市值為54.95億美元。

主動脈瓣狹窄可以透過經導管心臟瓣膜置換術進行手術治療，其中涉及更換受損的主動脈瓣而不是將其切除。瓣膜置換術通常需要胸骨切開術或物理性打開胸部的心臟直視手術。 TAVI 是透過一個微小的孔進行的，使所有胸骨保持完整。也可能需要經導管主動脈瓣或經主動脈瓣植入來恢復瓣膜的循環功能。

經導管心臟瓣膜置換術市場擴大的機會

經導管主動脈瓣置換術(TAVR) 是一種微創技術，由於主動脈瓣狹窄(AS) 盛行率不斷增加、老年人口不斷增加以及對微創手術的總體需求不斷成長，因此需求量很大。這些是經導管心臟瓣膜置換行業的重要驅動力。根據《心血管商業》報道，2021 年美國患者植入了 92,000 個 TAVR 瓣膜。由於疫情導致醫療業務整體下滑並影響醫療設備供應鏈，循環系統設備主要製造商收入大幅下降。

老年人口增加

推動經導管心臟瓣膜置換市場擴大的主要原因是人口老化，他們更容易罹患心臟病。在全球範圍內，老年人的數量正在迅速增加。老齡化會增加心臟衰竭的風險，老年人更容易罹患這些疾病。隨著人口老化增加這些疾病的盛行率，市場需求預計將增加並推動經導管心臟瓣膜置換市場的成長。

強化技術

經導管心臟瓣膜技術的發展取得了重大進展。這些發展正在創造更可靠、更安全、更容易植入的經導管心臟瓣膜產品。新型生物相容性和耐用材料的開發、使用 3D 列印來創建自訂心臟瓣膜，以及成像和導航技術的進步（允許更精確地放置心臟瓣膜）正在導致經導管心臟瓣膜置換術。這些是其中的一些推動市場成長的技術進步。

經股動脈手術方法越來越受歡迎

經股動脈手術方法由於其微創手術、恢復時間短和降低醫療費用等優點，預計將在經導管心臟瓣膜置換術行業中佔據主導地位。傳統手術涉及使用少量麻醉劑透過股動脈植入人工瓣膜。同時，在經導管心臟瓣膜置換市場中，經心尖類別預計將大幅成長。經心尖方法的優點在於，它允許操作者在裝置放置期間更容易地移動，並且由於主動脈瓣和左心室心尖附近而允許使用更大直徑的鞘套。

到醫院就診的病人增加

隨著越來越多的人去醫院和診所就診，對心臟病的診斷和治療的需求預計會增加，這將推動經導管心臟瓣膜置換市場在預測期內的成長。此外，工業創新持續改善前景。例如，為了擴大 AS 疾病患者的治療選擇，美國FDA 於 2021 年 9 月批准了 Abbott Laboratories, Inc. 的 Epic Plus 和 Epic Plus Supra 支架組織瓣膜。此外，主要製造商正在進行多個策略計劃，這將有助於開拓經導管心臟瓣膜置換市場。

製造商優先開發二尖瓣產品。

由於主要製造商加大研究投入，心臟瓣膜置換術術中的經導管二尖瓣置換術（TMVR）正在成為該行業的新前沿。由於患者治療需求未滿足以及經導管心臟瓣膜置換行業解決方案的稀缺，多家製造商正在開發新的 TMVR 設備並形成戰術性聯盟。例如，2021 年 9 月，雅培的 EpicTM Plus 和 Epic Plus Supra 支架組織瓣膜獲得美國食品藥物管理局(FDA) 批准，擴大了主動脈或二尖瓣疾病患者的治療選擇。

歐洲經導管心臟瓣膜置換市場預計將迅速擴大。

在預測期內，預計人口中 AS 疾病和主動脈瓣瓣膜閉鎖不全的盛行率將會增加，預計將推動歐洲市場的成長。經導管心臟瓣膜置換市場受到多個變數的影響，例如歐盟心臟瓣膜置換治療的增加、經濟成長、監管影響和新產品推出。例如，TAVR系統製造商Jena Valve Technology宣布將於2021年10月向歐洲推出其Trilogy心臟瓣膜系統。 Trilogy 在歐洲的正式商業首次亮相始於在德國多個中心進行的主動脈瓣瓣膜閉鎖不全1 (AR) 和主動脈瓣狹窄 1 (AS) 手術。

市場擴大策略

醫療保健系統和保險公司提供更廣泛的支付範圍可能會推動患者接受 TAVR 的機會增加以及經導管心臟瓣膜置換市場的成長。然而，也有機會將中度風險和低危險群患者涵蓋 TAVR 適應症。目前，各個市場相關人員正在進行臨床試驗，以評估經導管心臟瓣膜置換術在各種患者類別中的有效性和安全性，這顯著擴大了經導管心臟瓣膜置換術市場的潛力。

Aortic valve stenosis can be treated surgically using transcatheter heart valve replacement, which involves swapping out the damaged aortic valve instead of removing it. A sternotomy, or open-heart surgery when the chest is physically opened, is typically required for a valve replacement. The TAVI is carried out through microscopic holes, leaving all of the chest bones in place. Restoring the valve's circulatory system capabilities also entails implanting transcatheter aortic valves or transaortic valves.

Opportunities for the Transcatheter Heart Valve Replacement Market to increase

Transcatheter aortic valve replacement (TAVR) is a minimally invasive technique that is in high demand because of the increased prevalence of aortic valve stenosis (AS), the growing elderly population, and the rising need for less invasive procedures in general. These are some key drivers for the transcatheter heart valve replacement industry. In the United States, 92,000 TAVR valves were implanted in patients in 2021, according to Cardiovascular Business magazine. Major producers of cardiovascular equipment experienced significant revenue losses since the pandemic reduced the number of medical operations overall and affected the supply chain for medical devices.

Growing geriatric population

The key reason driving the expansion of the transcatheter heart valve replacement market is the ageing population, which is more prone to heart illness. Globally, the number of older individuals is rising quickly. Age increases a person's risk of heart failure, and older people are more likely to have these disorders. The market is projected to see increased demand due to the ageing population's increased prevalence of these diseases, which will propel the transcatheter heart valve replacement market growth.

Enhancement in Technology

Significant progress has been achieved in the creation of transcatheter heart valve technology. These developments have produced transcatheter heart valve products that are more dependable, secure, and simple to implant. The development of new biocompatible and long-lasting materials, the use of 3D printing to create custom heart valves, and the advancement of imaging and navigation technologies that enable more precise placement of the heart valve are some of the technological advancements that have fueled the transcatheter heart valve replacement market growth.

The transfemoral surgical approach is gaining popularity

The transfemoral surgical approach is anticipated to dominate the transcatheter heart valve replacement industry due to the advantages of minimally invasive surgery, quicker recovery periods, and reduced healthcare costs. The prosthetic valve is implanted through the femoral artery during the traditional operation using only a small amount of anaesthetic. On the other hand, the transcatheter heart valve replacement market is predicted to have significant growth in the transapical category. The transapical method is advantageous because it facilitates operator mobility during device installation and enables the use of sheaths with larger diameters because the aortic valve and left ventricular apex are nearby.

Increasing patient visits in hospitals

The need for heart disease diagnosis and treatment is anticipated to increase as more people visit hospitals and clinics, which will fuel the transcatheter heart valve replacement market growth throughout the projected period. Additionally, industrial innovation keeps improving prospects. For instance, to broaden the spectrum of therapeutic choices for patients with AS disease, the U.S. FDA authorised Abbott Laboratories, Inc.'s Epic Plus and Epic Plus Supra Stented Tissue Valves in September 2021. Additionally, important manufacturers take on several strategic projects that support the development of the transcatheter heart valve replacement market.

Manufacturers prioritise the creation of a mitral valve product.

Transcatheter mitral valve replacement (TMVR) in heart valve replacement is becoming a new frontier in the industry due to major manufacturers' growing investment in research. Patients' unmet treatment demands and the scarcity of solutions in the transcatheter heart valve replacement industry have prompted several producers to create new TMVR devices and form tactical alliances. For instance, in September 2021, The EpicTM Plus and Epic Plus Supra Stented Tissue Valves from Abbott were recently authorised by the U.S. Food and Drug Administration (FDA), expanding the range of treatment options for patients with aortic or mitral valve disease.

The market for transcatheter heart valve replacement in Europe is anticipated to expand quickly.

During the projection period, there is expected to be an increase in the prevalence of AS diseases and aortic regurgitation in the population, which will fuel Europe's market growth. The transcatheter heart valve replacement market is influenced by several variables, including an increase in heart valve replacement treatments, economic growth, regulatory repercussions, and new product introductions in the EU. For instance, JenaValve Technology, Inc., a producer of TAVR systems, announced the Trilogy heart valve system's introduction in Europe in October 2021. Trilogy's formal European commercial debut began with the operations, which comprised treating both aortic regurgitation1 (AR) and aortic stenosis1 (AS) in several centres around Germany.

Market Expansion Strategies

Increased patient access to TAVR and transcatheter heart valve replacement market growth may result from healthcare systems and insurance companies offering broader payment coverage. However, there is a chance to include intermediate and low-risk individuals in the TAVR indications. Clinical trials are now being conducted by various market players to assess the efficacy and safety of transcatheter heart valve replacement in various patient categories, which has the potential to considerably increase the transcatheter heart valve replacement market.

Market Key Developments

In December 2022, the newest generation transcatheter aortic valve implantation (TAVI) technology, Navitor, was made accessible by Abbott, a multinational healthcare business, for patients in India who have severe aortic stenosis and are at high or extremely high risk for surgery.
In September 2022, the FDA granted Edwards Lifesciences permission for its Sapien 3 transcatheter aortic valve, which is equipped with components that the firm says will form the basis of future heart valve implants.
In January 2022, a Hydra Transcatheter Aortic Heart Valve CE data study was published by Sahajanand Medical Technologies Limited in the American College of Cardiology's Cardiovascular Interventions publication.

Segmentation:

By Product

Transcatheter Aortic Valve Replacement
Transcatheter Mitral Valve Repair and Replacement
Transcatheter Pulmonary Valve Replacement

By Surgical Approach

Transfemoral Approach
Transapical Approach
Others

By End-Use

Hospitals
Cath Labs

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. TRANSCATHETER HEART VALVE REPLACEMENT MARKET, BY PRODUCT

5.1. Introduction
5.2. Transcatheter Aortic Valve Replacement
5.3. Transcatheter Mitral Valve Repair and Replacement
5.4. Transcatheter Pulmonary Valve Replacement

6. TRANSCATHETER HEART VALVE REPLACEMENT MARKET, BY SURGICAL APPROACH

6.1. Introduction
6.2. Transfemoral Approach
6.3. Transapical Approach
6.4. Others

7. TRANSCATHETER HEART VALVE REPLACEMENT MARKET, BY END-USE

7.1. Introduction
7.2. Hospitals
7.3. Cath Labs

8. TRANSCATHETER HEART VALVE REPLACEMENT MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others